Market Introduction
Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.
Market Overview and Dynamics
The Asia Pacific anti-viral therapies market is expected to reach US$ 16,118.52 million by 2027 from US$ 8,135.93 million in 2019; it is anticipated to grow at a CAGR of 9.0% during 2020–2027.The growth of the market is attributed to the increasing prevalence of viral diseases and outbreak of COVID-19 pandemic, growing R&D expenditures of pharmaceutical companies, and rising government support for research activities and clinical trials. However, high cost of drug development obstructs the growth of the market to a certain extent.
Key Market Segments
In terms of type, the branded drugs segment accounted for a larger share of the Asia Pacific anti-viral therapies market in 2019. In terms of mechanism of action, the nucleotide polymerase inhibitors segment accounted for the largest share of the market in 2019. In terms of application, the HIV segment accounted for the largest share of the Asia Pacific anti-viral therapies market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the Asia Pacific anti-viral therapies market report are the World Health Organization (WHO), International Society for Pharmaceutical Engineering, China Food and Drug Administration (CFDA), National Health Commission (NHC) of China, India Brand Equity Foundation (IBEF), and others.
Reasons to Buy Report
ASIA PACIFIC ANTI-VIRAL THERAPIESMARKET SEGMENTATION
By Type
By Mechanism of Action
By Application
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 8,135.93 Million |
| Market Size by 2027 | US$ 16,118.52 Million |
| CAGR (2020 - 2027) | 9.0% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Anti-Viral Therapies Market is valued at US$ 8,135.93 Million in 2019, it is projected to reach US$ 16,118.52 Million by 2027.
As per our report Asia Pacific Anti-Viral Therapies Market, the market size is valued at US$ 8,135.93 Million in 2019, projecting it to reach US$ 16,118.52 Million by 2027. This translates to a CAGR of approximately 9.0% during the forecast period.
The Asia Pacific Anti-Viral Therapies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Anti-Viral Therapies Market report:
The Asia Pacific Anti-Viral Therapies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Anti-Viral Therapies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Anti-Viral Therapies Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Anti-Viral Therapies Market
